©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2022; 28(48): 6791-6810
Published online Dec 28, 2022. doi: 10.3748/wjg.v28.i48.6791
Published online Dec 28, 2022. doi: 10.3748/wjg.v28.i48.6791
COVID-19 vaccination and liver disease
Sotaro Ozaka, Kazuhiro Mizukami, Kazunari Murakami, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, Japan
Sotaro Ozaka, Takashi Kobayashi, Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, Japan
Author contributions: Ozaka S wrote and edited the manuscript; Mizukami K reviewed and edited the manuscript; Murakami K and Kobayashi T provided oversight for the manuscript and revised it for important intellectual content; all authors issued final approval for the version to be submitted.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Sotaro Ozaka, MD, PhD, Assistant Professor, Department of Gas-troenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan. ozakaso@oita-u.ac.jp
Received: September 2, 2022
Peer-review started: September 2, 2022
First decision: October 20, 2022
Revised: November 7, 2022
Accepted: December 6, 2022
Article in press: December 6, 2022
Published online: December 28, 2022
Processing time: 116 Days and 1.6 Hours
Peer-review started: September 2, 2022
First decision: October 20, 2022
Revised: November 7, 2022
Accepted: December 6, 2022
Article in press: December 6, 2022
Published online: December 28, 2022
Processing time: 116 Days and 1.6 Hours
Core Tip
Core Tip: Patients with chronic liver disease (CLD), including cirrhosis, are a high-risk group for severe coronavirus disease 2019 (COVID-19). Presently, the results of several clinical trials for measuring the efficacy and safety of the available COVID-19 vaccines in patients with CLD have been reported. Given the increased rates of severity and mortality of COVID-19 in patients with CLD, the importance of aggressive vaccination in the effective management of severe acute respiratory syndrome coronavirus 2 infection should be emphasized. Although liver injury following COVID-19 vaccination has also been reported, it is infrequent and is not a factor in vaccine hesitancy.